News Releases

Date Title
04/19/2017 Summary ToggleEnanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017
04/18/2017 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2017
04/05/2017 Summary ToggleEnanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017
03/27/2017 Summary ToggleEnanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
03/14/2017 Summary ToggleEnanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
02/27/2017 Summary ToggleEnanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
02/08/2017 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016
02/06/2017 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
02/02/2017 Summary ToggleEnanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
01/24/2017 Summary ToggleEnanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C